J.P. Morgan Securities: The Crinetics Pharmaceuticals (CRNX.US) rating was reaffirmed and adjusted from superior to superior market rating, with a target price of $80.00.
摩根大通证券公司：重申Crinetics Pharmaceuticals(CRNX.US)评级，由优于大市调整至优于大市评级, 目标价80.00美元。
J.P. Morgan Securities: The Crinetics Pharmaceuticals (CRNX.US) rating was reaffirmed and adjusted from superior to superior market rating, with a target price of $80.00.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated